The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobery, T.
Right arrow Articles by Siliciano, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobery, T.
Right arrow Articles by Siliciano, R. F.
The Journal of Immunology, 1999, 162: 639-642.
Copyright © 1999 by The American Association of Immunologists


Cutting Edge

Cutting Edge: Induction of Enhanced CTL-Dependent Protective Immunity In Vivo by N-End Rule Targeting of a Model Tumor Antigen1

Timothy Tobery and Robert F. Siliciano2

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore MD 21205

There is much interest in vaccines that will enhance the induction of CTL. One mechanism to enhance Ag-specific CTL responses involves targeting Ag to undergo rapid cytoplasmic degradation by the N-end rule pathway. We have analyzed the ability of N-end rule targeting to confer protection in an immunization-challenge setting. Using the HIV-1 nef protein as a model tumor Ag, we found that in mice immunized with a vaccinia vector expressing a form of nef that is targeted for rapid cytoplasmic degradation, there was enhanced induction of nef-specific CTL and protection from a lethal challenge with the syngeneic CT26 tumor cells that had been transfected with nef. Protection from tumor challenge correlated with the magnitude of the CTL response. Thus, the targeting of tumor or viral Ags for rapid cytoplasmic degradation by the N-end rule pathway may represent a strategy for the induction of protective Ag-specific CTL responses in vivo.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Goldwich, S. S. C. Hahn, S. Schreiber, S. Meier, E. Kampgen, R. Wagner, M. B. Lutz, and U. Schubert
Targeting HIV-1 Gag into the Defective Ribosomal Product Pathway Enhances MHC Class I Antigen Presentation and CD8+ T Cell Activation
J. Immunol., January 1, 2008; 180(1): 372 - 382.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Ostankovitch, V. Robila, and V. H. Engelhard
Regulated Folding of Tyrosinase in the Endoplasmic Reticulum Demonstrates That Misfolded Full-Length Proteins Are Efficient Substrates for Class I Processing and Presentation
J. Immunol., March 1, 2005; 174(5): 2544 - 2551.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. N. Golovina, S. E. Morrison, and L. C. Eisenlohr
The Impact of Misfolding versus Targeted Degradation on the Efficiency of the MHC Class I-Restricted Antigen Processing
J. Immunol., March 1, 2005; 174(5): 2763 - 2769.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Z. Wang, C. La Rosa, S. Mekhoubad, S. F. Lacey, M. C. Villacres, S. Markel, J. Longmate, J. D. I. Ellenhorn, R. F. Siliciano, C. Buck, et al.
Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells
Blood, August 1, 2004; 104(3): 847 - 856.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Gottschalk
Killing 2 birds with 1 stone
Blood, December 15, 2003; 102(13): 4253 - 4254.
[Full Text] [PDF]


Home page
J. Exp. Biol.Home page
S. J. Dunachie and A. V. S. Hill
Prime-boost strategies for malaria vaccine development
J. Exp. Biol., November 1, 2003; 206(21): 3771 - 3779.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Shen, S. B. J. Wong, C. B. Buck, J. Zhang, and R. F. Siliciano
Direct Priming and Cross-Priming Contribute Differentially to the Induction of CD8+ CTL Following Exposure to Vaccinia Virus Via Different Routes
J. Immunol., October 15, 2002; 169(8): 4222 - 4229.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. N. Golovina, E. J. Wherry, T. N. J. Bullock, and L. C. Eisenlohr
Efficient and Qualitatively Distinct MHC Class I-Restricted Presentation of Antigen Targeted to the Endoplasmic Reticulum
J. Immunol., March 15, 2002; 168(6): 2667 - 2675.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. J. Shedlock and D. B. Weiner
DNA vaccination: antigen presentation and the induction of immunity
J. Leukoc. Biol., December 1, 2000; 68(6): 793 - 806.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
F. M. Orson, B. M. Kinsey, P. J. Hua, B. S. Bhogal, C. L. Densmore, and M. A. Barry
Genetic Immunization with Lung-Targeting Macroaggregated Polyethyleneimine-Albumin Conjugates Elicits Combined Systemic and Mucosal Immune Responses
J. Immunol., June 15, 2000; 164(12): 6313 - 6321.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Prevost-Blondel, E. Roth, F. M. Rosenthal, and H. Pircher
Crucial Role of TNF-{alpha} in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo
J. Immunol., April 1, 2000; 164(7): 3645 - 3651.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. P. N. Emmerich, A. K. Nussbaum, S. Stevanovic, M. Priemer, R. E. M. Toes, H.-G. Rammensee, and H. Schild
The Human 26 S and 20 S Proteasomes Generate Overlapping but Different Sets of Peptide Fragments from a Model Protein Substrate
J. Biol. Chem., July 7, 2000; 275(28): 21140 - 21148.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. C. F. Mulder and M. A. Muesing
Degradation of HIV-1 Integrase by the N-end Rule Pathway
J. Biol. Chem., September 15, 2000; 275(38): 29749 - 29753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.